Digital Treatment & Global Tobacco Use Reduction
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death - in adults...
- The study found that 6.5% of patients taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group.
- These findings primarily affect adults with obesity *and* pre-existing cardiovascular disease.
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death – in adults with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated notable weight loss, the cardiovascular safety signal is prompting a reassessment of its use in this specific patient population.
The Data: Key Findings from the SELECT Trial
The study found that 6.5% of patients taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33, indicating a 33% increased risk. Importantly, the weight loss achieved with semaglutide – an average of approximately 15% of initial body weight – did *not* appear to offset this cardiovascular risk. The findings were consistent across various subgroups, although some signals were more pronounced in patients with prior heart failure.
| Event | Semaglutide Group (%) | Placebo Group (%) |
|---|---|---|
| Cardiovascular Death | 1.5% | 1.2% |
| non-Fatal Stroke | 1.7% | 1.3% |
| Non-Fatal Heart Attack | 3.4% | 2.4% |
| MACE (Combined) | 6.5% | 4.9% |
Who is Affected? Understanding Patient Risk
These findings primarily affect adults with obesity *and* pre-existing cardiovascular disease. This includes individuals with a history of heart attack, stroke, peripheral artery disease, or heart failure. The trial did *not* include patients with type 2 diabetes, so the results cannot be directly extrapolated to that population. However, given that many individuals with type 2 diabetes also have cardiovascular risk factors, these findings warrant caution and further research in that group as well.
It’s crucial to differentiate between this population and individuals using semaglutide for weight loss *without* established cardiovascular disease. The risk-benefit profile may be different for these individuals, but ongoing monitoring remains essential.
Why Does This Matter? The Shifting Landscape of GLP-1 Receptor agonists
Semaglutide, like other GLP-1 receptor agonists, has been widely touted for its weight loss benefits and, in some earlier trials, potential cardiovascular protection – notably in patients with type 2 diabetes. The SELECT trial challenges this narrative, highlighting the importance of considering the specific patient population and underlying health conditions.This isn’t necessarily a condemnation of semaglutide, but a call for more nuanced prescribing practices.